Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service (ECAL)
Obesity, Severe Obesity, Sleep Apnoea
About this trial
This is an interventional treatment trial for Obesity focused on measuring weight management, obesity, severe obesity, structured dietary intervention, calorie restriction, indirect calorimetry, resting energy expenditure, resting metabolic rate, respiratory quotient, substrate oxidation, glycemic variability, insulin sensitivity, peripheral neuropathy
Eligibility Criteria
Inclusion Criteria:
- BMI > or equivalent to 30 kg/m2 to - 60 kg/m2
- Stable weight (change of <5% within 12 weeks before screening based on medical history)
- Subjects are well-motivated, capable and willing to learn how to undergo indirect calorimetry testing
- Willing and able to adhere to prohibitions and restrictions specified within this protocol
For Subjects participating in the glycaemic variability sub-study:
- Subject understands instructions on the use of continuous glucose monitor sensor and is willing to undergo appropriate training and testing
Exclusion Criteria:
- Taking weight loss medication within 12 weeks prior to randomisation
- Previous or planned bariatric surgery
- History of Type 1, Type 2 diabetes mellitus, DKA or diabetes secondary to pancreatitis
- Has HbA1c > or equal to 6.5% or Fasting Plasma Glucose > or equal to 7.0 mmol/L at screening.
NOTE: a one-time repeat measurement is allowed, if value of HbA1c and/or FPG is not consistent with prior values
- History of obesity with a known secondary cause (Cushing's disease/syndrome)
- Oral corticosteroid use (except in the short term use of a 7-10 day course)
- Ongoing, inadequately controlled thyroid disorder defined as thyroid-stimulating hormone > 6 mIU/litre or < 0.4 mIU/litre
- History of malignancy within 3 years before screening (or diagnosis of malignancy within this period)
- estimated glomerular filtration rate < 30 ml/min/1.73m2 on serum testing
- Alanine aminotransferase level is <2.0 times the upper limit of normal or total bilirubin is >1.5 times the upper limit of normal at screening
- Other major illness likely to preclude participation in the trial
- History of glucagonoma
- A myocardial infarction, unstable angina, revascularisation procedure (stent or bypass graft surgery) or cerebrovascular accident within 12 weeks before screening
Sites / Locations
- University Hospital Aintree
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
ECAL group
SC group
Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.